Lineage Cell Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2010 to Q2 2024.
  • Lineage Cell Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $94K.
  • Lineage Cell Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $1.39M, a 566% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $1.45M.
  • Lineage Cell Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$3.29M, a 155% decline from 2021.
  • Lineage Cell Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $5.94M, a 31.4% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.39M $94K +$273K Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $1.12M $103K -$332K -76.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $1.45M $1.65M +$1.37M +495% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $80K -$453K -$129K -39.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $209K -$179K +$2.37M +93% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$2.16M $435K +$1.13M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$3.29M $277K +$50K +22% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$3.34M -$324K +$1.68M +83.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$5.02M -$2.55M -$4.66M -220% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$358K -$697K -$6.3M -112% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.94M $227K -$6.64M -96.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $12.6M -$2M -$778K -63.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $13.4M $2.12M +$2.24M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $11.1M $5.6M +$6.59M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.52M $6.87M +$5.33M +348% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$811K -$1.23M +$7.86M +86.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$8.67M -$128K +$20.4M +99.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$29M -$990K -$48.7M -102% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $19.6M $1.53M +$36.8M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$17.1M -$9.08M -$86M -112% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $68.9M -$20.5M -$25M -555% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $93.8M $47.7M +$99.2M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$5.34M -$35.2M +$32.1M +47.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$37.4M $76.9M +$48.6M +172% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$86M $4.5M +$12M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$98.1M -$51.5M -$114M -183% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $15.6M -$67.3M -$70.7M -2091% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $86.3M $28.3M -$10.5M -27.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $96.8M -$7.54M -$43.2M -121% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $140M $62.2M +$62.4M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $77.6M $3.38M -$401K -10.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 $78M $38.8M +$39.4M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $38.6M $35.6M +$35.4M +15458% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $3.19M -$239K +$26K +9.81% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $3.16M $3.78M +$4.34M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-15
Q3 2015 -$1.18M -$585K -$459K -364% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 -$725K $229K +$74K +47.7% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$799K -$265K -$326K -536% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$473K -$563K -$521K -1245% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-16
Q3 2014 $47.9K -$126K -$71.6K -132% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 $120K $155K +$234K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 -$115K $60.8K +$89.4K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 -$204K -$41.8K +$52.6K +55.7% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-15
Q3 2013 -$257K -$54.4K -$77.3K -337% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
Q2 2013 -$179K -$79.2K -$164K -193% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$15K -$28.6K +$290K +91% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q4 2012 -$305K -$94.4K -$279K -151% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-11
Q3 2012 -$25.9K $22.9K +$27.2K Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-12
Q2 2012 -$53.1K $85.1K +$104K Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
Q1 2012 -$157K -$319K -$400K -493% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-10
Q4 2011 $243K $185K Oct 1, 2011 Dec 31, 2011 10-K 2014-03-17
Q3 2011 -$4.25K +$2.34M +99.8% Jul 1, 2011 Sep 30, 2011 10-Q 2011-11-08
Q2 2011 -$19.3K +$19K +49.6% Apr 1, 2011 Jun 30, 2011 10-Q 2011-08-09
Q1 2011 $81.2K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10
Q3 2010 -$2.34M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$38.4K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.